ArticleEvidence-based complementary and alternative medicine : eCAM2018
Tetramethylpyrazine and Paeoniflorin Inhibit Oxidized LDL-Induced Angiogenesis in Human Umbilical Vein Endothelial Cells via VEGF and Notch Pathways.
Article in Evidence-based complementary and alternative medicine : eCAM, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Systematic review of Chinese medicine for the treatment of atherosclerosis.Frontiers in cardiovascular medicine · 2025Pooled it
- The role of tetramethylpyrazine and paeoniflorin in modulating iron metabolism and ferroptosis: innovative strategies for atherosclerosis treatment.Frontiers in pharmacology · 2026Article
- Beyond metabolism and blood flow: toward an inflammation-metabolism axis paradigm for herbal medicine in obesity-related coronary heart disease.Frontiers in cardiovascular medicine · 2026Article
- Taohong Siwu Decoction Regulates MSC-Mediated H-Type Angiogenesis to Accelerate Bone Fracture Healing Through VHL/HIF-1α Ubiquitination.Mediators of inflammation · 2026Article
- Review
- Paeoniflorin improves atherosclerosis by regulating the gut microbiota and fecal metabolites.mSystems · 2025Article
- Angiogenesis within atherosclerotic plaques: Mechanical regulation, molecular mechanism and clinical diagnosis.Mechanobiology in medicine · 2025Review
- Tetramethylpyrazine promotes osteo-angiogenesis during bone fracture repair.Journal of orthopaedic surgery and research · 2025Article
- Effect of Naoluoxintong formula and its split prescriptions on cerebral vascular regeneration in rats with the cerebral ischemia-reperfusion.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2023Article
- Glycoside combinations of Buyang Huanwu decoction ameliorate atherosclerosis via STAT3, HIF-1, and VEGF.Naunyn-Schmiedeberg's archives of pharmacology · 2023Article
- Identification of a Novel Angiogenesis Signalling circSCRG1/miR-1268b/NR4A1 Pathway in Atherosclerosis and the Regulatory Effects of TMP-PF In Vitro.Molecules (Basel, Switzerland) · 2023Article
- Protective effects of paeoniflorin on cardiovascular diseases: A pharmacological and mechanistic overview.Frontiers in pharmacology · 2023Review
- The Role of the VEGF Family in Atherosclerosis Development and Its Potential as Treatment Targets.International journal of molecular sciences · 2022Review
- Paeoniflorin Inhibits EMT and Angiogenesis in Human GlioblastomaFrontiers in oncology · 2022Article
- Inhibition of LOXL1-AS1 alleviates oxidative low-density lipoprotein induced angiogenesis via downregulation of miR-590-5p mediated KLF6/VEGF signaling pathway.Cell cycle (Georgetown, Tex.) · 2021Article
- Tetramethylpyrazine Alleviates Endothelial Glycocalyx Degradation and Promotes Glycocalyx Restoration via TLR4/NF-κB/HPSE1 Signaling Pathway During Inflammation.Frontiers in pharmacology · 2021Article
- Combined Therapy with Traditional Chinese Medicine and Antiplatelet Drugs for Ischemic Heart Disease: Mechanism, Efficacy, and Safety.Evidence-based complementary and alternative medicine : eCAM · 2021Review
- Research Advances in Cardio-Cerebrovascular Diseases ofFrontiers in pharmacology · 2021Review
- Tetramethylpyrazine Ameliorates Peritoneal Angiogenesis by Regulating VEGF/Hippo/YAP Signaling.Frontiers in pharmacology · 2021Article
- Treatment of tibial dyschondroplasia with traditional Chinese medicines: "Lesson and future directions".Poultry science · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atherosclerotic plaque angiogenesis is key factor in plaque instability and vulnerability, and low concentrations of oxidized low density lipoprotein (ox-LDL) promote the in vitro angiogenesis of endothelial cells and play an important role in plaque angiogenesis. Ligusticum chuanxiong Hort. and Radix Paeoniae Rubra herb pair in Chinese medicine obtains the optimum therapeutic efficacy in atherosclerosis, and their major active ingredients tetramethylpyrazine (TMP) and paeoniflorin (PF) are reported to alleviate atherosclerosis. The aim of this study was to investigate the effects of TMP and PF on ox-LDL-induced angiogenesis and the underlying mechanism. Human umbilical vein endothelial cells (HUVECs) were incubated with ox-LDL and were then treated with TMP, PF, or a combination of TMP and PF. Cell proliferation, migration, tube formation, and the expression of angiogenesis-related proteins were measured. Synergism was evaluated using the combination index in cell proliferation. We found that TMP and PF attenuated the in vitro angiogenesis in ox-LDL-induced HUVECs. In addition, the combination of TMP and PF not only inhibited the ox-LDL-induced expression of CD31, vascular endothelial growth factor (VEGF), and VEGF receptor 2 (VEGFR2) but also decreased the ox-LDL-induced expression of Notch1, Jagged1, and Hes1. In summary, the combination of TMP and PF suppresses ox-LDL-induced angiogenesis in HUVECs by inhibiting both the VEGF/VEGFR2 and the Jagged1/Notch1 signaling pathways, which might contribute to the stability of plaques in atherosclerosis.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.